Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2017-08, Vol.19 (8), p.1097-1105
• Main Authors: Holden, Sarah E., Morgan, Christopher Ll, Qiao, Qing, Jenkins‐Jones, Sara, Berni, Ellen R., Currie, Craig J.
• Format: Article
• Language: English
• Subjects: Antidiabetics; Cohort analysis; Cohort Studies; Combined Modality Therapy - economics; Cost of Illness; Costs; Costs and Cost Analysis; database research; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - economics; Diabetes Mellitus, Type 2 - therapy; Drug Administration Schedule; Drug Costs; exenatide; Female; Follow-Up Studies; Health Care Costs; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - economics; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - administration & dosage; Insulin - economics; Insulin - therapeutic use; insulin therapy; Male; Materials management; Middle Aged; observational study; Patient Acceptance of Health Care; Peptides - administration & dosage; Peptides - economics; Peptides - therapeutic use; Primary Health Care - economics; Retrospective Studies; Secondary Care - economics; State Medicine; type 2 diabetes; United Kingdom; Venoms - administration & dosage; Venoms - economics; Venoms - therapeutic use
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.12916

Aims Type 2 diabetes is a major health problem placing increasing demands on healthcare systems. Our objective was to estimate healthcare resource use and related financial costs following treatment with exenatide‐based regimens prescribed as once‐weekly (EQW) or twice‐daily (EBID) formulations, compared with regimens based on basal insulin (BI). Materials and methods This retrospective cohort study used data from the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). Patients with type 2 diabetes who received exenatide or BI between 2009 and 2014 as their first recorded exposure to injectable therapy were selected. Costs were attributed to primary care contacts, diabetes‐related prescriptions and inpatient admissions using standard UK healthcare costing methods (2014 prices). Frequency and costs were compared between cohorts before and after matching by propensity score using Poisson regression. Results Groups of 8723, 218 and 2180 patients receiving BI, EQW and EBID, respectively, were identified; 188 and 1486 patients receiving EQW and EBID, respectively, were matched 1:1 to patients receiving BI by propensity score. Among unmatched cohorts, total crude mean costs per patient‐year were £2765 for EQW, £2549 for EBID and £4080 for BI. Compared with BI, the adjusted annual cost ratio (aACR) was 0.92 (95% CI, 0.91‐0.92) for EQW and 0.82 (95% CI, 0.82‐0.82) for EBID. Corresponding costs for the propensity‐matched subgroups were £2646 vs £3283 (aACR, 0.80, 0.80‐0.81) for EQW vs BI and £2532 vs £3070 (aACR, 0.84, 0.84‐0.84) for EBID vs BI. Conclusion Overall, exenatide once‐weekly and twice‐daily‐based regimens were associated with reduced healthcare resource use and costs compared with basal‐insulin‐based regimens.